Insider · CIK 0002064744
Pichi Luo Chiang
Files at KZR (Kezar Life Sciences, Inc.). First filing Jul 3, 2025, latest Jul 3, 2025.
Pichi Luo Chiang files SEC Form 4 as officer at KZR (Kezar Life Sciences, Inc.). Since Jul 3, 2025, Pichi Luo Chiang has reported 0 open-market buys worth $0 and 1 open-market sell worth $1,130, the latest filed on Jul 3, 2025.
A track record needs three past buys with six months of prices behind them; Pichi Luo Chiang has 0, so none is measured yet.
The newest scored trade: sold $1,130 of KZR on Jul 2, 2025, filed Jul 3, 2025, scored 23 (weak).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | Kezar Life Sciences, Inc. | $1,130 264 shares | -9% | - |
Transactions
Every row this insider has filed, 15 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | UTender of shares Common Stock | -2,711 | - | - | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -10,000 | $0.00 | $0 | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -12,500 | $0.00 | $0 | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -17,500 | $0.00 | $0 | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -7,500 | $0.00 | $0 | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -1,199 | $0.00 | $0 | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -2,052 | $0.00 | $0 | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -599 | $0.00 | $0 | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -2,401 | $0.00 | $0 | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -2,499 | $0.00 | $0 | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -2,899 | $0.00 | $0 | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -2,899 | $0.00 | $0 | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -4,999 | $0.00 | $0 | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -7,999 | $0.00 | $0 | 0 | May 11, 2026 |
| Jul 2, 2025 | KZR Kezar Life Sciences, Inc. | SOpen-market sale Common Stock | -264 | $4.28 | $1,130 | 2,711 | Jul 3, 2025 |
Questions about Pichi Luo Chiang
Answered from the filings on this page, as of the latest one.
Is Pichi Luo Chiang buying or selling?
Not in the last 12 months. Pichi Luo Chiang's latest open-market trade on SEC Form 4 was sold $1,130 of KZR on Jul 2, 2025.
How did Pichi Luo Chiang's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Pichi Luo Chiang has 0.
Where does Pichi Luo Chiang file Form 4?
Pichi Luo Chiang has filed Form 4 at KZR (Kezar Life Sciences, Inc.) as SVP, Corporate Controller. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.